NEWS

Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility

Read article

Resources

Resource centre

Webinar

Formulation strategies for poorly soluble molecules - Pharmaceutics and biopharmaceutics considerations

This presentation uses expert insight and case studies to explore formulation and solubility challenges and discuss the best strategies and technologies for advancing poorly soluble molecules, to deliver success.

Leveraging Bioanalysis to Accelerate Drug Development Programs: Challenges and Considerations

Join Quotient’s Vice President of Bioanalysis, Dr Stuart McDougall, as he discusses how best to leverage bioanalysis within drug development programs to accelerate timelines & enhance the likelihood of clinical & commercial success.

Bioanalytical services to accelerate drug development

Delivering rapid bioanalytical data is critical to drug development. From drug discovery, through to preclinical and clinical studies, understanding drug exposure and behavior are imperative to dose selection, and accelerating drugs to clinic and commercialization. Through the use of robust bioanalytical techniques, biological samples can be processed and analyzed to identify and quantify compounds of interest, such as small molecules and their metabolites, as well as peptides, proteins, nucleic acids and other analytes.

Scientific Posters

Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations

Access our latest poster from AAPS 2021- Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations. The purpose of this study is to review practical experiences of head to head pharmaceutical and clinical comparisons of MUPs and matrix tablet platforms to identify an optimal MR formulation.

Scientific Posters

EuPFI 2021 - Taste Assessment Study of Belumosudil to Inform an Integrated Paediatric Formulation Development Program

Presented at the annual EuPFI event, this poster documents the project of Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders.

Scientific Posters

ISSX NA 2021 - An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and absolute bioavailability of Nolasiban in Healthy Female Subjects

Presented at the 24th North American ISSX Meeting, in this poster, we determine Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects, via an integrated radiolabelled study.

Integrated Programs: Early Development

Simplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.

Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics

This webinar reviews the challenges when developing a peptide formulation, investigates the best route of delivery for your molecule, alongside looking into formulation strategies and manufacturing considerations, before exploring options for an integrated approach to accelerate peptide development.

Quotient Sciences Corporate Brochure 2021

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Our corporate brochure provides a key summary of who we are, what we represent, our services and our marketplace differentiation.

Stability Capabilities

Designated team of highly experienced personnel who control all aspects of sample management and liaise closely with clients throughout the lifecycle of stability studies. Our aim is to provide robust, sound data on which shelf life and expiration dates for drug substance and drug products can be based. Whatever the phase of development our team can offer support. We also offer a stability protocol creation service if clients prefer not to supply stability protocols themselves. Robust systems are in place to ensure complete tracking of samples from receipt, through stability storage and time-point testing (or shipment if required), to study end.

Microbiology Services

Quotient Sciences' extensive experience permits testing of difficult products that have not previously been analyzed. We are specialists at the microbial analysis of radiolabelled compounds and are able to handle cytotoxic, high potency compounds and controlled substances. Our flexible approach allows us to offer both on-site microbiological testing and analysis of products made off-site.

Isotope Labelling

Whether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.

Bioanalytical Services

Determining drug exposure is vital for the assessment of drug safety and efficacy. Quotient's Bioanalytical team, develop and refine methods so exposure can be assessed reliably and accurately in a variety of biological matrices.

Drug Substance Formulation Development Clinical Trial Manufacturing Commercial Manufacturing Bioanalysis Clinical Pharmacology Data Sciences Drug Development Consulting

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.